Literature DB >> 20346735

Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production.

Anne P Liao1, Mohammad Salajegheh, Chris Morehouse, Remedios Nazareno, Ronald G Jubin, Bahija Jallal, Yihong Yao, Steven A Greenberg.   

Abstract

To determine the potential consequences of plasmacytoid dendritic cell (pDC) accumulation in tissue sites observed in several autoimmune diseases, we measured type 1 interferon production from circulating human pDCs as a function of pDC concentration. The effects of interferon-alpha and blockade of the type 1 interferon receptor (IFNAR) on human pDC type 1 interferon and interferon-inducible transcription and protein production were measured. Human pDCs became far more efficient producers of interferon-alpha at concentrations beyond those normally present in blood, through an IFNAR-dependent mechanism. Extracellular interferon-alpha increased pDC production of type 1 interferons. The accumulation of pDCs in diseased tissue sites allows marked non-linear amplification of type 1 interferon production locally. The role of the IFNAR-dependent mechanism of interferon production by human pDCs is greater than previously suggested. IFNAR blockade has potential for diminishing type 1 interferon production by all human cells. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346735      PMCID: PMC2892243          DOI: 10.1016/j.clim.2010.02.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  39 in total

1.  Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

Authors:  Ronan J Walsh; Sek Won Kong; Yihong Yao; Bahija Jallal; Peter A Kiener; Jack L Pinkus; Alan H Beggs; Anthony A Amato; Steven A Greenberg
Journal:  Arthritis Rheum       Date:  2007-11

2.  Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis.

Authors:  Consuelo M López de Padilla; Abbe N Vallejo; Kelly T McNallan; Richard Vehe; Stephen A Smith; Allan B Dietz; Stanimir Vuk-Pavlovic; Ann M Reed
Journal:  Arthritis Rheum       Date:  2007-05

Review 3.  Systemic lupus erythematosus: all roads lead to type I interferons.

Authors:  Virginia Pascual; Lorant Farkas; Jacques Banchereau
Journal:  Curr Opin Immunol       Date:  2006-10-02       Impact factor: 7.486

4.  Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage.

Authors:  William Vermi; Silvia Lonardi; Mauro Morassi; Cristina Rossini; Regina Tardanico; Marina Venturini; Raffaella Sala; Angela Tincani; Pietro Luigi Poliani; Pier Giacomo Calzavara-Pinton; Lorenzo Cerroni; Amerigo Santoro; Fabio Facchetti
Journal:  Immunobiology       Date:  2009-07-21       Impact factor: 3.144

5.  Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18.

Authors:  Marco Tucci; Cosima Quatraro; Lucia Lombardi; Cecilia Pellegrino; Franco Dammacco; Franco Silvestris
Journal:  Arthritis Rheum       Date:  2008-01

6.  Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications.

Authors:  Steven A Greenberg
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

7.  Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus.

Authors:  Jennifer M McNiff; Daniel H Kaplan
Journal:  J Cutan Pathol       Date:  2007-11-12       Impact factor: 1.587

8.  Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.

Authors:  Zoe Waibler; Martina Anzaghe; Holger Ludwig; Shizuo Akira; Siegfried Weiss; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 9.  Inflammatory myopathies: disease mechanisms.

Authors:  Steven A Greenberg
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

Review 10.  Type I interferon and lupus.

Authors:  Lars Rönnblom; Gunnar V Alm; Maija-Leena Eloranta
Journal:  Curr Opin Rheumatol       Date:  2009-09       Impact factor: 5.006

View more
  13 in total

1.  Long Noncoding RNA Signatures Induced by Toll-Like Receptor 7 and Type I Interferon Signaling in Activated Human Plasmacytoid Dendritic Cells.

Authors:  Rochelle C Joslyn; Adriana Forero; Richard Green; Stephen E Parker; Ram Savan
Journal:  J Interferon Cytokine Res       Date:  2018-09       Impact factor: 2.607

Review 2.  Dermatomyositis and type 1 interferons.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

3.  Virus Multiplicity of Infection Affects Type I Interferon Subtype Induction Profiles and Interferon-Stimulated Genes.

Authors:  Luna A Zaritsky; Jacquelyn R Bedsaul; Kathryn C Zoon
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

4.  Extracellular Matrix-Associated Pathways Promote the Progression of Gastric Cancer by Impacting the Dendritic Cell Axis.

Authors:  Zhenlin Wang; Zunyun Wang; Xianyu Hu; Qijun Han; Ke Chen; Gang Pang
Journal:  Int J Gen Med       Date:  2021-10-13

5.  Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Robert D Schreiber; Brian R Lawson; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  J Immunol       Date:  2012-11-21       Impact factor: 5.422

6.  Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness.

Authors:  Kristen L Chen; Jay Patel; Majid Zeidi; Maria Wysocka; Muhammad M Bashir; Basil Patel; Spandana Maddukuri; Barbara White; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2021-03-04       Impact factor: 7.590

Review 7.  Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.

Authors:  Renaud Felten; Florence Scher; Flora Sagez; François Chasset; Laurent Arnaud
Journal:  Drug Des Devel Ther       Date:  2019-05-08       Impact factor: 4.162

8.  Plasmacytoid DCs From Patients With Sjögren's Syndrome Are Transcriptionally Primed for Enhanced Pro-inflammatory Cytokine Production.

Authors:  Maarten R Hillen; Aridaman Pandit; Sofie L M Blokland; Sarita A Y Hartgring; Cornelis P J Bekker; Eefje H M van der Heijden; Nila H Servaas; Marzia Rossato; Aike A Kruize; Joel A G van Roon; Timothy R D J Radstake
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

9.  Respiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodies.

Authors:  Marcel A Schijf; Michael V Lukens; Debby Kruijsen; Nathalie O P van Uden; Johan Garssen; Frank E J Coenjaerts; Belinda Van't Land; Grada M van Bleek
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

10.  Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.

Authors:  Jeffrey M Riggs; Richard N Hanna; Bhargavi Rajan; Kamelia Zerrouki; Jodi L Karnell; Divya Sagar; Inna Vainshtein; Erika Farmer; Kimberly Rosenthal; Chris Morehouse; Melissa de Los Reyes; Kevin Schifferli; Meina Liang; Miguel A Sanjuan; Gary P Sims; Roland Kolbeck
Journal:  Lupus Sci Med       Date:  2018-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.